Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.75 |
| ▸ | DGKA | P23743 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25492396 | 0.90 | TSHR (0.72) | TSHRDGKAMEN1KMT2ALMNA | |
| SCHEMBL5271388 | 0.89 | TSHR (0.65) | TSHRDGKAMEN1KMT2ALMNA | |
| SCHEMBL11647199 | 0.89 | TSHR (0.65) | TSHRDGKAMEN1KMT2ALMNA | |
| SCHEMBL28600261 | 0.87 | TSHR (0.62) | TSHRDGKAMEN1KMT2ALMNA | |
| SCHEMBL2137161 | 0.87 | TSHR (0.62) | TSHRDGKAALDH1A1MAPTDNM1 | |
| SCHEMBL28075596 | 0.87 | TSHR (0.62) | TSHRDGKAMEN1KMT2ALMNA | |
| SCHEMBL50039 | 0.87 | TSHR (1.00) | TSHRMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL28238018 | 0.87 | TSHR (1.00) | TSHRMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL429505 | 0.86 | TSHR (0.61) | TSHRDGKAMEN1KMT2ALMNA | |
| SCHEMBL27638433 | 0.86 | TSHR (0.61) | TSHRDGKAMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968168-B2 | Isocyanate production method | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-04-06 | — | — | US | disclosed |
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-04-16 | — | — | US | disclosed |
| US-8962784-B2 | Isocyanate terminated macromer and formulation thereof for use as an internal adhesive or sealant | ETHICON, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8470954-B2 | Diisocyanate terminated macromer and formulation thereof for use as an internal adhesive or sealant | ETHICON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8324292-B2 | Medically acceptable formulation of a diisocyanate terminated macromer for use as an internal adhesive or sealant | ETHICON, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8084625-B2 | Crosslinking agent, crosslinking method, method of controlling gene expression, and method of examining gene function | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8084625-B2 | Crosslinking agent, crosslinking method, method of controlling gene expression, and method of examining gene function | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8071663-B2 | Medically acceptable formulation of a diisocyanate terminated macromer for use as an internal adhesive or sealant | ETHICON, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7968668-B2 | Diisocyanate terminated macromer and formulation thereof for use as an internal adhesive or sealant | ETHICON INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100158849-A1 | ISOCYANATE TERMINATED MACROMER AND FORMULATION THEREOF FOR USE AS AN INTERNAL ADHESIVE OR SEALANT | ETHICON, INC. | 2010-06-24 | — | — | US | disclosed |
| US-7728097-B2 | Method of making a diisocyanate terminated macromer | ETHICON, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090222038-A1 | MEDICALLY ACCEPTABLE FORMULATION OF A DIISOCYANATE TERMINATED MACROMER FOR USE AS AN INTERNAL ADHESIVE OR SEALANT | ETHICON, INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221731-A1 | MEDICALLY ACCEPTABLE FORMULATION OF A DIISOCYANATE TERMINATED MACROMER FOR USE AS AN INTERNAL ADHESIVE OR SEALANT | ETHICON, INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090023140-A1 | CROSSLINKING AGENT, CROSSLINKING METHOD, METHOD OF CONTROLLING GENE EXPRESSION, AND METHOD OF EXAMINING GENE FUNCTION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090023140-A1 | CROSSLINKING AGENT, CROSSLINKING METHOD, METHOD OF CONTROLLING GENE EXPRESSION, AND METHOD OF EXAMINING GENE FUNCTION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20070276121-A1 | DIISOCYANATE TERMINATED MACROMER AND FORMULATION THEREOF FOR USE AS AN INTERNAL ADHESIVE OR SEALANT | ETHICON, INC. | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023140-A1 | CROSSLINKING AGENT, CROSSLINKING METHOD, METHOD OF CONTROLLING GENE EXPRESSION, AND METHOD OF EXAMINING GENE FUNCTION | DCLRE1A, RNGTT, NSUN2 | TSHR 3242/4885DGKA 1451/4885MEN1 4488/4885 |
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | IDH3A, ALKBH3, CPS1 | TSHR 4661/4885DGKA 1635/4885MEN1 2818/4885 |
| US-10968168-B2 | Isocyanate production method | IDH3A, ALKBH3, CPS1 | TSHR 4661/4885DGKA 1635/4885MEN1 2818/4885 |
| US-20100158849-A1 | ISOCYANATE TERMINATED MACROMER AND FORMULATION THEREOF FOR USE AS AN INTERNAL ADHESIVE OR SEALANT | ICAM1, ILK, MACF1 | TSHR 4859/4885DGKA 3393/4885MEN1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.